Vilin Bio Med voluntarily submits September 2026 governance report
VILINBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vilin Bio Med, listed on NSE Emerge and exempt from certain governance rules, voluntarily follows main-board governance standards and submitted its integrated governance report for the quarter ended September 30, 2026. Its four-member board includes two independent directors. No investor complaints, cyber incidents, fines, tax disputes, loans, guarantees, or securities were reported. It retained full ownership of Axia Pharma and Vilo Speciality Pharma.
Stronger disclosure may support investor confidence, but no earnings or operating change was announced, so the immediate stock impact is likely small.